Generics dominate as Bayer fights on against Indian Nexavar licence

More than a year after India issued its first ever compulsory licence in the area of medicines for Bayer's anticancer Nexavar (sorafenib tosylate), cut-price generic versions of the product dominate the Indian market, even as the multinational fights on to defend its intellectual property rights.